This Notice of Funding Opportunity (NOFO) invites applications proposing innovative strategies to target and manipulate brain cell subtypes that are altered in aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs). ADRDs include frontotemporal disorders (FTD), Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED).
Specifically, the goal of this NOFO is to encourage the development and utilization of sophisticated tools that pair breakthroughs in adeno-associated virus (AAV) capsid engineering with enhancer element identification to do the following:
To achieve the goal, this NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for pilot activities to demonstrate proof-of-principle. The R33 phase provides up to 3 years of support for implementation activities, including hypothesis testing.
Deadlines:
RFA-AG-25-024 Expiration Date October 08, 2024
Sponsor Institute/Organizations: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Oct 07, 2024
Varies
Affiliation: National Institutes of Health
Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.